There is progress on the integration of digital pathology systems and proprietary algorithms designed to help pathologists make diagnoses. This month, Visiopharm and Omnyx LLC, announced a joint venture. On its own, in Europe last year, Visiopharm earned a CE mark for its “in vitro diagnostic (IVD) software module for the breast cancer marker HER2.” …
October 21, 2013 “Intelligence: Late Breaking Lab News” Read More »
